Výsledky vyhledávání - "Matus Studeny"

Phase I trial of the DLL3/CD3 bispecific T-cell engager BI 764532 in DLL3-positive small-cell lung cancer and neuroendocrine carcinomas

Autor: Martin Wermke, Enriqueta Felip, Valentina Gambardella, Yasutoshi Kuboki, Daniel Morgensztern, Zohra Oum’ Hamed, Meiruo Liu, Matus Studeny, Taofeek K Owonikoko

Publikováno v: Scientia

T-cell engager; Eeuroendocrine carcinoma; Small-cell lung cancer Acoplador de cèl·lula T; Carcinoma neuroendocrí; Càncer de pulmó de cèl·lules petites Acoplador de célula T; Carcinoma neuroendocrino; Cáncer de pulmón de células pequeñas P

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e83791285194b01116298cd0de0ee7c
https://doi.org/10.2217/fon-2022-0196

Zobrazit plný text záznamu

A phase I, open-label, dose-escalation trial of BI 764532, a DLL3/CD3 bispecific antibody, in patients (pts) with small cell lung carcinoma (SCLC) or other neuroendocrine neoplasms expressing DLL3

Autor: Enriqueta Felip, Yasutoshi Kuboki, Daniel Morgensztern, Matus Studeny, Martin Wermke, Taofeek K. Owonikoko, Valentina Gambardella, Zohra Oum'Hamed, Junxian Geng

Publikováno v: Journal of Clinical Oncology. 39:TPS8588-TPS8588

TPS8588 Background: First-line standard of care for pts with metastatic SCLC and neuroendocrine carcinoma (NEC) is platinum-based chemotherapy ± immunotherapy. While the addition of anti-PD1 antibodies has improved outcomes, nearly all pts relapse a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::84f878ca000d81eb2da4fe82336f3216
https://doi.org/10.1200/jco.2021.39.15_suppl.tps8588

Zobrazit plný text záznamu

A multicentre, open-label, phase-I/randomised phase-II study to evaluate safety, pharmacokinetics, and efficacy of nintedanib vs. sorafenib in European patients with advanced hepatocellular carcinoma

Autor: Markus Peck-Radosavljevic, Arsene-Bienvenu Loembe, Yuk Ting Ma, Laetitia Fartoux, David Schnell, Janet Graham, Julia Hocke, Paul Ross, Daniel H. Palmer, Andrzej Deptała, Matus Studeny, Tim Meyer

Publikováno v: British Journal of Cancer

Background: \ud This multicentre, open-label, phase-I/randomised phase-II trial evaluated safety, pharmacokinetics, maximum-tolerated-dose (MTD) per dose-limiting toxicities (DLTs), and efficacy of nintedanib vs. sorafenib in European patients with u

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e7e888e571a39896fc792d7ffda6dbc
https://eprints.gla.ac.uk/159941/1/159941.pdf

Zobrazit plný text záznamu

Reduction of nontarget infection and systemic toxicity by targeted delivery of conditionally replicating viruses transported in mesenchymal stem cells

Autor: Erika L. Spaeth, Candelaria Gomez-Manzano, Jennifer L. Dembinski, Frank C. Marini, Juan Fueyo, Matus Studeny, Michael Andreeff

Publikováno v: Cancer Gene Therapy. 17:289-297

The fiber-modified adenoviral vector Delta-24-RGD (D24RGD) offers vast therapeutic potential. Direct injection of D24RGD has been used to successfully target ovarian tumors in mice. However, systemic toxicity, especially in the liver, profoundly limi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f1f089fa1bfb8d63230a16796c6e71fe
https://doi.org/10.1038/cgt.2009.67

Zobrazit plný text záznamu

Mesenchymal Stem Cells in Cancer: Tumor-Associated Fibroblasts and Cell-Based Delivery Vehicles

Autor: Michael Andreeff, Frank C. Marini, A. Kate Sasser, Jennifer L. Dembinski, Matus Studeny, Brett Hall

Publikováno v: International Journal of Hematology. 86:8-16

Recent evidence suggests that mesenchymal stem cells (MSC) selectively home to tumors, where they contribute to the formation of tumor-associated stroma. This effect can be opposed by genetically modifying MSC to produce high levels of anti-cancer ag

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bba9f5d2747ef525b9775daf63c28e31
https://doi.org/10.1532/ijh97.06230

Zobrazit plný text záznamu

Rationale and Design for the LUME-Colon 1 Study: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Nintedanib Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Patients With Advanced Colorectal Cancer Refractory to Standard Treatment

Autor: Takayuki Yoshino, Eric Van Cutsem, Julia Hocke, Matus Studeny, Zohra Oum'Hamed, Josep Tabernero

Publikováno v: Clinical colorectal cancer. 15(1)

Background Clinical studies of antivascular endothelial growth factor (anti-VEGF) agents have demonstrated that angiogenesis is critical to colorectal cancer (CRC) tumor growth and metastasis. Nintedanib is a triple angiokinase inhibitor of VEGF, pla

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d81b3c1995da171f99bdaa14c1292c0
https://pubmed.ncbi.nlm.nih.gov/26603056

Zobrazit plný text záznamu

Effect of small angiokinase inhibitor nintedanib (BIBF 1120) on QT interval in patients with previously untreated, advanced renal cell cancer in an open-label, phase II study

Autor: Tim Eisen, Igor Bondarenko, Arsene-Bienvenu Loembe, Claudia Dallinger, Yaroslav Shparyk, Robert Jones, Matus Studeny, Yasser Khder, Graham Temple, Gudrun Wallenstein, N. MacLeod

Publikováno v: Investigational new drugs. 31(5)

Purpose Some targeted anticancer agents are associated with serious ventricular tachyarrhythmias, which may be predicted by electrocardiographic evaluation of drug-related QT prolongation. We studied the effects of nintedanib (BIBF 1120; an oral, tri

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b6475874c6c2a04882f8097eee54ac07
https://pubmed.ncbi.nlm.nih.gov/23625328

Zobrazit plný text záznamu

Mesenchymal Stem/Stromal Cells as Cellular Vehicles for Tumor Targeting

Autor: Xiaoyang Ling, Jennifer L. Dembinski, Shannon Kidd, Fredrick Lang, Michael Andreeff, Zhizong Zeng, Ann H. Klopp, Frank C. Marini, Matus Studeny, Keri L. Watson, Erika L. Spaeth, Brett Hall

Publikováno v: Gene-Based Therapies for Cancer ISBN: 9781441961013

Data published over the last 10 years suggest that mesenchymal stem/stromal cells (MSC) possess the innate capacity to home to sites of inflammation, including tumors and wounding microenvironments. Evidence suggests that the increased production of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5ec118a7cf6337b9ef63d63b8e4aa334
https://doi.org/10.1007/978-1-4419-6102-0_8

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání